SCHEMBL10037091

SCHEMBL10037091

CCCCC/C(C)=C(\CCl)CCCCC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 3/20 0.39
TSHR P16473 6/20 0.39
ALDH1A1 P00352 4/20 0.39
CES2 O00748 4/20 0.39
CES1 P23141 4/20 0.39
AKR1B1 P15121 1/20 0.37
GPR84 Q9NQS5 6/20 0.36
PPARG P37231 6/20 0.36
PPARD Q03181 6/20 0.36
PPARA Q07869 6/20 0.36
HDAC11 Q96DB2 5/20 0.36
TLR2 O60603 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
FABP4 P15090 2/20 0.36
PTPN1 P18031 2/20 0.36
SLC22A6 Q4U2R8 1/20 0.36
SLC22A8 Q8TCC7 1/20 0.36
MEN1 O00255 1/20 0.36
ESR1 P03372 1/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8551412 0.85 TSHR (0.46) FAAHTSHRALDH1A1CES2CES1
SCHEMBL8551408 0.85 TSHR (0.46) FAAHTSHRALDH1A1CES2CES1
SCHEMBL7932408 0.85 CES2 (0.46) TSHRALDH1A1CES2CES1AKR1B1
Ammonia Solution, Strong SCHEMBL9455180 0.80 CES2 (0.46) TSHRALDH1A1CES2CES1GPR84
Hydrochloric Acid SCHEMBL6905421 0.78 CES2 (0.44) TSHRALDH1A1CES2CES1GPR84
SCHEMBL11051191 0.78 CES1 (0.40) TSHRALDH1A1CES2CES1AKR1B1
SCHEMBL11051195 0.78 CES1 (0.40) TSHRALDH1A1CES2CES1AKR1B1
SCHEMBL7668411 0.76 CES1 (0.43) TSHRALDH1A1CES2CES1AKR1B1
SCHEMBL31744489 0.76 CES2 (0.42) TSHRALDH1A1CES2CES1GPR84
SCHEMBL10342857 0.76 CES2 (0.53) TSHRALDH1A1CES2CES1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142781-A1 Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States MAGNESIUM DIAGNOSTICS INC. (US) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142781-A1 Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States PLPBP, ECE1, MCU FAAH 2098/4885TSHR 714/4885ALDH1A1 3725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.